



## Company Overview

Ra Medical Systems' advanced excimer laser systems are tools for use in the treatment of vascular diseases. We believe our products enhance patients' quality of life by restoring blood-flow in arteries.

**DABRA** is our minimally-invasive excimer laser and disposable catheter system that is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of peripheral artery disease, or PAD, both above- and below-the-knee. DABRA breaks down plaque to its fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. Unlike many treatments for PAD that may damage the arterial wall, DABRA quickly, photochemically dissolves plaque with minimal vascular trauma.

DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA was granted CE mark clearance in September 2016 for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions.

## Stock Overview

Symbol	RMED
Exchange	NYSE American
Market Cap	23.55m
Last Price	\$3.35
52-Week	\$2.38 - \$9.82

09/27/2021 04:00 PM EDT

## Investor Relations

LHA Investor Relations  
Jody Cain  
[Jcain@lhai.com](mailto:Jcain@lhai.com)  
T: (310) 691-7100

## Ra Medical Systems, Inc.

2070 Las Palmas Drive  
Carlsbad, CA 92011

## Recent News

### [Ra Medical Systems to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference](#)

Sep 7 2021, 4:05 PM EDT

### [Ra Medical Systems Reports 2021 Second Quarter Financial Results](#)

Aug 16 2021, 4:05 PM EDT

### [Ra Medical Systems Announces Sale of Pharos Dermatology Business](#)

Aug 16 2021, 4:03 PM EDT

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.